Drug and Country Characteristics Associated with Global Approval and Launch of FDA-Approved Novel Therapeutics
Clicks: 1
ID: 320512
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #17 of 90 articles by views in Health Affairs Scholar
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Introduction Global availability of novel therapeutics varies widely across countries and is strongly associated with national income. However, whether drug characteristics are associated with global approval and launch remains unclear. Methods We conducted a cross-sectional study of therapeutics approved by the US Food and Drug Administration (FDA) between 2008 and 2019, examining global regulatory approval and market launch through February 2026 using Citeline Pharmaprojects. Results Among 396 FDA-approved novel therapeutics, approval or launch of at least one therapeutic was identified in 119 countries outside the US. Therapeutics were approved and launched in a median of 36 and 17 countries, respectively. In multivariable drug-level analyses, biologics and therapeutics developed by large sponsors were approved or launched in more countries, infectious disease therapeutics in fewer countries. Drug innovation status, orphan designation, unmet medical need, and safety risk were not associated with global approval or launch. At country level, high-income level, regulatory maturity, larger populations, and greater healthcare resources were associated with more approvals and launches. Conclusion Global approval and launch of FDA-approved novel therapeutics were associated more strongly with country and sponsor capacity than drug-level characteristics. Improving global access may require addressing both regulatory and commercial barriers to approval and launch.
| Reference Key |
openalex_W7167905647
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Mengyuan Fu, Joshua D. Wallach, Anthony D. So, Harry Doernberg, Xiangyu Li, Xiaodong Guan, Reshma Ramachandran, Joseph S. Ross |
| Journal | Health Affairs Scholar |
| Year | 2026 |
| DOI |
10.1093/haschl/qxag181
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.